Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...
US pharma giant Merck & Co today announced that the European Commission (EC) has conditionally approved two indications for Welireg (belzutifan), its oral hypoxia-inducible factor-2 alpha (HIF-2α) ...
On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, as monotherapy for: Adult ...
"This is an important moment, and we are pleased that WELIREG, a first-in-class HIF-2α inhibitor, can now potentially help these patients in need." This approval allows marketing of WELIREG for ...
Merck (MRK) announced that the European Commission has conditionally approved WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, ...
“This is an important moment, and we are pleased that WELIREG, a first-in-class HIF-2α inhibitor ... a PD-1 or PD-L1 inhibitor and at least two VEGF targeted therapies, is based on progression ...
Clinic Center of Human Gene Research, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. (C.W., W.X., S.J., Y.W., J ...
“This is an important moment, and we are pleased that WELIREG, a first-in-class HIF-2α inhibitor, can now potentially help ... including a PD-1 or PD-L1 inhibitor and at least two VEGF targeted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback